HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-24
DOI
10.1038/s41388-020-01394-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
- (2019) Camilla Salvagno et al. NATURE CELL BIOLOGY
- Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
- (2019) Kerry A. Rogers et al. LEUKEMIA
- CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
- (2019) Amira A. Barkal et al. NATURE
- Chronic lymphocytic leukaemia: from genetics to treatment
- (2019) Francesc Bosch et al. Nature Reviews Clinical Oncology
- PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia
- (2019) Yu-Chen Enya Chen et al. LEUKEMIA
- Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
- (2018) Tilly Varughese et al. CLINICAL INFECTIOUS DISEASES
- HDAC inhibition helps post-MI healing by modulating macrophage polarization
- (2018) Denise Kimbrough et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies
- (2018) Karl R. VanDerMeid et al. Cancer Immunology Research
- Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma
- (2018) Ji-Won Jung et al. OncoImmunology
- Cancer immunotherapy targeting the CD47/SIRPα axis
- (2017) Kipp Weiskopf EUROPEAN JOURNAL OF CANCER
- Class IIa HDACs inhibitor TMP269 promotes M1 polarization of macrophages after spinal cord injury
- (2017) Xiangbei Qi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
- (2017) Jennifer L. Guerriero et al. NATURE
- Control of Phagocytosis by Microbial Pathogens
- (2017) Eileen Uribe-Querol et al. Frontiers in Immunology
- New insights into the multidimensional concept of macrophage ontogeny, activation and function
- (2016) Florent Ginhoux et al. NATURE IMMUNOLOGY
- Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients
- (2016) M Burgess et al. ONCOGENE
- Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression
- (2016) Giovanni Galletti et al. Cell Reports
- Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
- (2015) Ali Roghanian et al. CANCER CELL
- Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
- (2015) A. K. Church et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
- (2015) B S Hanna et al. LEUKEMIA
- Nurse like cells: chronic lymphocytic leukemia associated macrophages
- (2015) Frédéric Boissard et al. LEUKEMIA & LYMPHOMA
- Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients
- (2014) Michaël Van Damme et al. Epigenetics
- Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
- (2014) Nuray Gül et al. JOURNAL OF CLINICAL INVESTIGATION
- CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
- (2013) M. Burgess et al. CLINICAL CANCER RESEARCH
- Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
- (2013) Mercedes Lobera et al. Nature Chemical Biology
- Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells
- (2012) Linda Marek et al. JOURNAL OF MEDICINAL CHEMISTRY
- CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cellsin vitro
- (2012) Melinda Burgess et al. LEUKEMIA & LYMPHOMA
- A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
- (2010) Margaret E. Ackerman et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Toll-Like Receptor Stimulation Enhances Phagocytosis and Intracellular Killing of Nonencapsulated and Encapsulated Streptococcus pneumoniae by Murine Microglia
- (2009) S. Ribes et al. INFECTION AND IMMUNITY
- Lysine Acetylation Regulates Bruton’s Tyrosine Kinase in B Cell Activation
- (2009) Zhijian Liu et al. JOURNAL OF IMMUNOLOGY
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
- (2008) Nagma Khan et al. BIOCHEMICAL JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now